Biomarker Diagnostics

Biomarker Services for Neurodegenerative Disease

Two female researchers in a laboratoryScottish Brain Sciences provides high-quality biomarker testing services to support the early detection and diagnosis of Alzheimer’s disease and other neurodegenerative conditions.

Our UKAS ISO 15189-accredited laboratory delivers robust, clinically reliable data to pharmaceutical, biotech and academic partners—supporting clinical trials, translational research and the development of next-generation diagnostics.

Get in touch to discuss how we can support your biomarker strategy, clinical study or research programme commercial@brainsciences.scot 

Leadership in Biomarkers – Our Capabilities

We offer a comprehensive range of biomarker services using our Roche cobas® Core e801 autoanalyser, including:

  • Plasma and CSF biomarker analysis including pTau181 and pTau217 assays
  • Sample processing and biobanking
  • Support and delivery of clinical trial biomarker strategies
  • Data generation for translational and observational studies

Our laboratory works with well-characterised cohorts and established protocols to ensure consistency, reproducibility and scientific rigour.

We have established industry collaborations and trusted by leading pharmaceutical partners, including Roche and Eli Lilly

Image shows blood samples in test tubes.

Biomarker Services for Alzheimer’s disease testing

Accredited. Clinically interpreted. Trusted for patient care.

Our clinical biomarker service runs on the Roche cobas® Core e801 autoanalyser using Roche Elecsys® CE-IVD assays, the same platform now anchoring biomarker pathways across leading memory services worldwide.

Every test is run in our facility based in Scotland – by our team, on our instruments – nothing is sent overseas, and nothing is subcontracted.

Every clinical report we issue includes interpretive commentary placing the result in clinical context, supported by our named and renowned specialists. For referring clinicians, this turns a laboratory result into a piece of clinical evidence ready to inform the next decision.

CSF testing

Our CSF-based clinical laboratory service is designed to confirm Alzheimer’s disease pathology through the measurement of CSF pTau181 / Aβ42 ratio.

For pricing, contracting and to learn more, please contact  labenquiries@brainsciences.scot

Plasma testing

We anticipate to offer our blood-based biomarker clinical service (pTau217 and pTau181) from summer 2026.

Please contact labenquiries@brainsciences.scot to register interest and for further information

Supporting clinical trials and diagnostics

Biomarkers are transforming how neurodegenerative diseases are detected, stratified and treated. We work with partners across the development pathway to:

  • Enable earlier and more accurate detection of Alzheimer’s disease
  • Support patient stratification and trial recruitment
  • Generate reliable biomarker endpoints
  • Advance the development of diagnostic biomarker tools

Explore biomarker solutions. Contact our team today.

Send an email